The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic imatinib ...
Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia (CML) patients who do not respond well to tyrosine ...
Please provide your email address to receive an email when new articles are posted on . In this video, Christine McMahon, MD, discusses the results of the phase 3 ASC4FIRST study, pertaining to ...
Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Danziten, a nilotinib formulation, is approved for CML without mealtime restrictions, enhancing patient adherence and reducing cardiotoxicity risks. The drug offers equivalent efficacy to Tasigna, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback